Compared to Estimates, Catalyst (CPRX) Q1 Earnings: A Look at Key Metrics

Core Insights - Catalyst Pharmaceutical (CPRX) reported a revenue of $141.42 million for Q1 2025, marking a year-over-year increase of 43.6% and exceeding the Zacks Consensus Estimate by 8.92% [1] - The earnings per share (EPS) for the same quarter was $0.68, which is a significant increase from $0.38 a year ago, representing an EPS surprise of 28.30% over the consensus estimate of $0.53 [1] Revenue Breakdown - Product revenue from FIRDAPSE was $83.73 million, surpassing the average estimate of $77.44 million [4] - Product revenue from FYCOMPA reached $35.63 million, exceeding the estimated $31.80 million [4] - Product revenue from AGAMREE was $22.04 million, compared to the average estimate of $20.04 million [4] - Total product revenue net was $141.40 million, compared to the estimated $129.40 million, reflecting a 43.6% increase year-over-year [4] - Revenue from licenses and other sources was $0.02 million, significantly below the estimated $0.88 million, indicating a 69.1% decrease compared to the previous year [4] Stock Performance - Catalyst's shares have returned +7.8% over the past month, while the Zacks S&P 500 composite has increased by +10.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]